Literature DB >> 9973222

Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas.

J Y Kim1, M E Sutton, D J Lu, T A Cho, L C Goumnerova, L Goritchenko, J R Kaufman, K K Lam, A L Billet, N J Tarbell, J Wu, J C Allen, C D Stiles, R A Segal, S L Pomeroy.   

Abstract

Elevated expression of the neurotrophin-3 (NT-3) receptor TrkC by childhood medulloblastomas is associated with favorable clinical outcome. Here, we provide evidence that TrkC is more than simply a passive marker of prognosis. We demonstrate that: (a) medulloblastomas undergo apoptosis in vitro when grown in the presence of NT-3; (b) overexpression of TrkC inhibits the growth of intracerebral xenografts of a medulloblastoma cell line in nude mice; and (c) trkC expression by individual tumor cells is highly correlated with apoptosis within primary medulloblastoma biopsy specimens. TrkC-mediated NT-3 signaling promotes apoptosis by activating multiple parallel signaling pathways and by inducing immediate-early gene expression of both c-jun and c-fos. Considered collectively, these results support the conclusion that the biological actions of TrkC activation affect medulloblastoma outcome by inhibiting tumor growth through the promotion of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973222

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  Neurotrophins: roles in neuronal development and function.

Authors:  E J Huang; L F Reichardt
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

2.  TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.

Authors:  Jamie L Croucher; Radhika Iyer; Nanxin Li; Valentina Molteni; Jon Loren; W Perry Gordon; Tove Tuntland; Bo Liu; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-14       Impact factor: 3.333

Review 3.  Pediatric surgical neuro-oncology: current best care practices and strategies.

Authors:  James T Rutka; John S Kuo
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

Review 4.  Emerging treatments and gene expression profiling in high-risk medulloblastoma.

Authors:  Iacopo Sardi; Duccio Cavalieri; Maura Massimino
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

5.  The TrkC receptor induces apoptosis when the dependence receptor notion meets the neurotrophin paradigm.

Authors:  Servane Tauszig-Delamasure; Li-Ying Yu; Jorge Ruben Cabrera; Jimena Bouzas-Rodriguez; Catherine Mermet-Bouvier; Catherine Guix; Marie-Claire Bordeaux; Urmas Arumäe; Patrick Mehlen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-08       Impact factor: 11.205

6.  Growth-inhibitory effect of neurotrophin-3-secreting adipose tissue-derived mesenchymal stem cells on the D283-MED human medulloblastoma cell line.

Authors:  Young-Hoon Kim; Seung Hee Cho; Soo Jung Lee; Seung Ah Choi; Ji Hoon Phi; Seung-Ki Kim; Kyu-Chang Wang; Byung-Kyu Cho; Chae-Yong Kim
Journal:  J Neurooncol       Date:  2011-07-01       Impact factor: 4.130

7.  Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia.

Authors:  Q Liu; J Schwaller; J Kutok; D Cain; J C Aster; I R Williams; D G Gilliland
Journal:  EMBO J       Date:  2000-04-17       Impact factor: 11.598

8.  Methylation and expression patterns of tropomyosin-related kinase genes in different grades of glioma.

Authors:  Mahalakshmi Palani; R Arunkumar; Arrambakam Janardhanam Vanisree
Journal:  Neuromolecular Med       Date:  2014-05-20       Impact factor: 3.843

Review 9.  Medulloblastoma: from molecular pathology to therapy.

Authors:  Alessandra Rossi; Valentina Caracciolo; Giuseppe Russo; Krzysztof Reiss; Antonio Giordano
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

10.  Magnetic resonance imaging of patched heterozygous and xenografted mouse brain tumors.

Authors:  Aaron L Nelson; Sibel A Algon; Jeeva Munasinghe; Ondrea Graves; Liliana Goumnerova; Deborah Burstein; Scott L Pomeroy; John Y H Kim
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.